Disease · MONDO_0005391

restless legs syndrome

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. restless legs syndrome. Diseases, record MONDO_0005391. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0005391

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: restless legs syndrome; Open Targets
Open Targets ID: MONDO_0005391; Open Targets
Other names: Ekbom syndrome, Ekbom's syndrome, restless leg syndrome, restless legs; Open Targets
Disease Ontology: DOID:0050425; Disease Ontology
MeSH: D012148; MeSH
NCI Thesaurus: C84501; NCI Thesaurus
Highest stage of its drugs: Approval, for 6 of its 47 drugs, from DailyMed, EMA Human Drugs and PMDA; Open Targets

Drugs47

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
ROTIGOTINE	CHEMBL1303	Small molecule	Approval	DailyMed and EMA Human Drugs	27	22	22	Drugs and targets
PRAMIPEXOLE	CHEMBL301265	Small molecule	Approval	EMA Human Drugs	21	18	18	Drugs and targets
GABAPENTIN ENACARBIL	CHEMBL1628502	Small molecule	Approval	DailyMed and PMDA	20	18	18	Drugs and targets
GABAPENTIN	CHEMBL940	Small molecule	Approval	DailyMed	5	4	4	Drugs and targets
ROPINIROLE HYDROCHLORIDE	CHEMBL1200411	Small molecule	Approval	DailyMed	4	0	0	Drugs and targets
PRAMIPEXOLE DIHYDROCHLORIDE	CHEMBL3182733	Small molecule	Approval	DailyMed	2	0	0	Drugs and targets
ROPINIROLE	CHEMBL589	Small molecule	Phase 3	ClinicalTrials.gov	16	16	16	Drugs and targets
FERRIC CARBOXYMALTOSE	CHEMBL2108597		Phase 3	ClinicalTrials.gov	5	5	4	Drugs and targets
PREGABALIN	CHEMBL1059	Small molecule	Phase 3	ClinicalTrials.gov	5	5	5	Drugs and targets
LEVODOPA	CHEMBL1009	Small molecule	Phase 3	ClinicalTrials.gov and TTD	4	3	3	Drugs and targets

1 to 10 of 47

See all 47 drugs

Targets81

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
DRD2	D(2) dopamine receptor	7	D2-like dopamine receptor agonist; Dopamine D2 receptor agonist; Dopamine D2 receptor partial agonist	Approval	https://conductscience.org/library/genes/1813	Drugs and targets
DRD3	D(3) dopamine receptor	6	D2-like dopamine receptor agonist; Dopamine D3 receptor agonist	Approval	https://conductscience.org/library/genes/1814	Drugs and targets
DRD4	D2-like dopamine receptor	5	D2-like dopamine receptor agonist	Approval	https://conductscience.org/library/genes/1815	Drugs and targets
CACNA1B	Voltage-dependent N-type calcium channel subunit alpha-1B	4	Voltage-gated N-type calcium channel alpha-1B subunit blocker; Voltage-gated calcium channel modulator	Approval	https://conductscience.org/library/genes/774	Drugs and targets
CACNA1A	Voltage-gated calcium channel	3	Voltage-gated calcium channel modulator	Approval	https://conductscience.org/library/genes/773	Drugs and targets
CACNA1C	Voltage-gated calcium channel	3	Voltage-gated calcium channel modulator	Approval	https://conductscience.org/library/genes/775	Drugs and targets
CACNA1D	Voltage-gated calcium channel	3	Voltage-gated calcium channel modulator	Approval	https://conductscience.org/library/genes/776	Drugs and targets
CACNA1E	Voltage-gated calcium channel	3	Voltage-gated calcium channel modulator	Approval	https://conductscience.org/library/genes/777	Drugs and targets
CACNA1F	Voltage-gated calcium channel	3	Voltage-gated calcium channel modulator	Approval	https://conductscience.org/library/genes/778	Drugs and targets
CACNA1G	Voltage-gated calcium channel	3	Voltage-gated calcium channel modulator	Approval	https://conductscience.org/library/genes/8913	Drugs and targets

1 to 10 of 81

See all 81 targets

Trials107

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 3 more are not shown, since the checks do not confirm them.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT01327339	REQUIP RLS Post Marketing Surveillance		755	2011-04-01	Restless Legs Syndrome	ROPINIROLE	Its record names the disease	ClinicalTrials.gov
NCT00806026	Long Term Study Of Pregabalin In Idiopathic Restless Legs Syndrome Patients	Phase 3	731	2012-09-27	Idiopathic Restless Legs Syndrome	PREGABALIN	Its record names the disease	ClinicalTrials.gov
NCT01113710	Non-interventional Study (NIS) in Patients With Restless Legs Syndrome in Daily Practise		687	2012-09-28	Idiopathic Restless Legs Syndrome	ROTIGOTINE	Its record names the disease	ClinicalTrials.gov
NCT00333359	XP13512 (Gabapentin Enacarbil) Extension Study in Patients With Restless Legs Syndrome.	Phase 3	581	2011-06-23	Restless Legs Syndrome	GABAPENTIN ENACARBIL	Its record names the disease	ClinicalTrials.gov
NCT00721279	Sifrol (Pramipexole) Onset of Action and Impact: a 12-weeks Observational Study in Patients With Primary Restless Legs Syndrome		549	2010-01-08	Restless Legs Syndrome	PRAMIPEXOLE	Its record names the disease	ClinicalTrials.gov
NCT01668667	Gabapentin Enacarbil (GSK1838262) Adult Restless Leg Syndrome (RLS) Post Marketing Commitment Study	Phase 4	501	2014-11-17	Restless Legs Syndrome	GABAPENTIN ENACARBIL	Its record names the disease	ClinicalTrials.gov
NCT03053427	A Study of Oral Dosing of Gabapentin Enacarbil in Japanese Restless Legs Syndrome Patients	Phase 4	375	2019-07-10	Restless Legs Syndrome (RLS)	GABAPENTIN ENACARBIL	Its record names the disease	ClinicalTrials.gov
NCT00472199	Long-term Efficacy, Safety and Tolerability of Pramipexole in Patients With Idiopathic Moderate to Severe Restless Legs Syndrome (RLS)	Phase 4	331	2009-11-17	Restless Legs Syndrome	PRAMIPEXOLE	Its record names the disease	ClinicalTrials.gov
NCT00311363	Long-Term Study of Gabapentin Enacarbil (GEn, XP13512) vs. Placebo in Patients With Restless Legs Syndrome.	Phase 3	327	2011-05-25	Restless Legs Syndrome	GABAPENTIN ENACARBIL	Its record names the disease	ClinicalTrials.gov
NCT00365352	XP13512 vs. Placebo in Patients With Restless Legs Syndrome.	Phase 3	325	2011-05-11	Restless Legs Syndrome	GABAPENTIN ENACARBIL	Its record names the disease	ClinicalTrials.gov

1 to 10 of 107

See all 107 trials

Comparisons in its trials37

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
De-novo Patients vs Pre-treated Patients: serious adverse events	0 of 452	2 of 97	549	NCT00721279	Trial comparisons
Gabapentin Enacarbil vs Placebo: deaths from any cause	0 of 189	0 of 186	375	NCT03053427	Trial comparisons
Gabapentin Enacarbil vs Placebo: serious adverse events	3 of 189	0 of 186	375	NCT03053427	Trial comparisons
Pramipexole vs Placebo: serious adverse events	8 of 166	3 of 163	329	NCT00472199	Trial comparisons
Pramipexole vs Placebo: serious adverse events	3 of 202	0 of 103	305	NCT00654498	Trial comparisons
Pramipexole vs Placebo: Diagnosis of Classified Augmentation According to Independent Expert Panel	18 of 152	14 of 149	301	NCT00472199	Trial comparisons
Pramipexole vs Placebo: Worsening of RLS Symptoms (by at Least 4 Points in the IRLS Total Score Compared to Baseline) After Treatment Discontinuation	14 of 135	2 of 133	268	NCT00472199	Trial comparisons
GEn 1200 mg vs Placebo: serious adverse events	2 of 127	0 of 132	259	NCT00748098	Trial comparisons
GEn 1200 mg vs Placebo: Number of Participants Who Were Defined as Clinical Global Impression of Illness (CGI-I) Scale Responders at Week 4/10 Using LOCF	91 of 123	46 of 127	250	NCT00748098	Trial comparisons
GEn 1200 mg vs Placebo: Number of PLMAI Responders at Week 4/10 Using LOCF	64 of 121	44 of 123	244	NCT00748098	Trial comparisons

1 to 10 of 37

See all 37 comparisons in its trials

Papers from its trials44

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
28366342	RESULT	1	PubMed
23964267	RESULT	1	PubMed
21705273	RESULT	1	PubMed
20920156	RESULT	1	PubMed
20817595	RESULT	1	PubMed
20813583	RESULT	1	PubMed
20629075	RESULT	1	PubMed
19480225	RESULT	1	PubMed
18753003	RESULT	1	PubMed
18515185	RESULT	1	PubMed

1 to 10 of 44

See all 44 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0005391

GET https://conductscience.org/api/diseases/v1/MONDO_0005391/drugs?page=2

API reference For AI assistants